PDF(Pubmed)
Abstract：
This retrospective study aimed to evaluate the impact of radiation dose on the outcomes of stereotactic radiosurgery (SRS) for benign meningiomas and determine an optimal dosing strategy for balancing tumor control and treatment-related toxicity. Clinical data of 147 patients with 164 lesions treated between 2014 and 2022 were reviewed. Primary outcomes included progression-free survival (PFS), local control rate (LCR), and radiation-induced toxicity, with secondary outcomes focusing on LCR and radiation-induced peritumoral edema (PTE) in two dose groups (≥14 Gy and <14 Gy). The results revealed a median follow-up duration of 47 months, with 1-year, 2-year, and 5-year PFS rates of 99.3%, 96.7%, and 93.8%, respectively, and an overall LCR of 95.1%. Radiation-induced toxicity was observed in 24.5% of patients, primarily presenting mild symptoms. Notably, no significant difference in LCR was found between the two dose groups (p = 0.628), while Group 2 (<14 Gy) exhibited significantly lower PTE (p = 0.039). This study concludes that SRS with a radiation dose < 14 Gy demonstrates comparable tumor control with reduced toxicity, advocating consideration of such dosing to achieve a balance between therapeutic efficacy and safety.
摘要：
这项回顾性研究旨在评估辐射剂量对良性脑膜瘤立体定向放射外科（SRS）结果的影响，并确定平衡肿瘤控制和治疗相关毒性的最佳给药策略。回顾性分析2014年至2022年期间147例164个病灶患者的临床资料。主要结果包括无进展生存期（PFS），本地控制率（LCR），和辐射诱导的毒性，在两个剂量组（≥14Gy和<14Gy）中，次要结局集中在LCR和放射诱导的瘤周水肿（PTE）。结果显示，中位随访时间为47个月，1年,2年,5年PFS率为99.3%，96.7%,和93.8%，分别,总体LCR为95.1%。在24.5%的患者中观察到辐射引起的毒性,主要表现为轻微症状。值得注意的是,两个剂量组之间的LCR没有发现显着差异（p=0.628），而第2组(<14Gy)表现出显著较低的PTE(p=0.039)。这项研究的结论是，辐射剂量<14Gy的SRS显示出可比的肿瘤控制与降低的毒性，主张考虑这种给药，以实现治疗功效和安全性之间的平衡。
